50 Million euro investment for LUMC spin-off RougeTx advances therapies for inherited bleeding disorders.
From scientific discovery to first application in the clinic. This is the remarkable 20-year journey of human induced pluripotent stem cells (iPSC), made possible by a series of technological advances. iPSCs have now revolutionized disease modeling, drug discovery and toxicity testing. In addition, iPSC-based cell therapies for various diseases have now reached market approval. A review in Nature Medicine by reNEW Principal Investigator Christine Mummery and four other experts discusses the past, present and future of iPSCs.
“Since its discovery two decades ago, iPSC technology has made tremendous progress towards clinical application. This is a fantastic moment to reflect on this success, but also to look forward and envision the next chapter of iPSC-based medicine,” said Mummery.
20 years of breakthroughs and obstacles
iPSCs did not reach their current position overnight. The past years have been marked by major breakthroughs. Advances in cellular reprogramming, genome editing, directed differentiation and tissue modelling have been crucial to this progress. Together, these innovations have established iPSCs as a platform capable of modelling complex diseases and testing potential treatments. In parallel, the first results from iPSC-derived cell replacement therapies are emerging, including applications for Parkinson’s disease, heart failure, and eye diseases.
Despite these successes, the translation of iPSC-based therapies and disease models still faces hurdles. Disease models struggle with issues of standardization and variability in their intended use. For iPSC-based therapies, biological variability, long-term safety, consistent and scalable production, and regulatory requirements are recurring challenges that can impact their translation into the clinic.
The evolution ahead
In the review, Mummery and her collaborators explore how integration of other transformative technologies – such as automation and artificial intelligence – could help overcome these challenges and transform iPSCs into major contributors to clinical medicine. The authors present a roadmap towards a future in which iPSC move from experimental modalities into standardized, precision-oriented platforms for regenerative medicine and drug discovery.
Mummery concludes: “With iPSC-based biomedicine entering a new phase of clinical translation, the coming 20 years will show whether these once bespoke experimental models can become robust and widely adopted platforms and, ultimately, a new paradigm in contemporary medicine.”
